Retatrutide vs Tirzepatide

How do they actually differ?

Evidence tier: 1 for tirzepatide pharmacology; Tier 2 for retatrutide — Phase 2 NEJM data plus topline Phase 3 readouts as of mid-2026.

Tirzepatide is a dual agonist of the GLP-1 and GIP receptors. Retatrutide adds a third pathway: glucagon receptor agonism, on top of the same GLP-1 and GIP backbone. The mechanistic rationale for adding glucagon is that GLP-1 monotherapy reduces resting energy expenditure over time as patients lose weight — a metabolic adaptation that drives plateau and post-discontinuation regain. Glucagon receptor agonism increases hepatic glucose production and energy expenditure, partially offsetting the slowdown. Both agents are weekly subcutaneous injections with similar half-lives (~5-6 days). Tirzepatide titrates 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg; retatrutide titrates 2 → 4 → 8 → 12 mg in the published Phase 3 design. Both produce dose-dependent gastrointestinal adverse events as the dominant side-effect category. Retatrutide's added glucagon arm carries theoretical risks around hepatic glucose handling, heart rate elevation, and potential for more pronounced lipolysis — these are being characterized in the TRIUMPH program. Tirzepatide is FDA-approved and on pharmacy shelves; retatrutide is investigational. The matrix has dosing, half-life, and Phase 2/3 numbers.

Who should choose retatrutide?

Evidence tier: 5 — speculative until FDA approval. No retatrutide patient should choose it outside a clinical trial in 2026.

Retatrutide is currently available only through clinical trial enrollment. Eli Lilly's TRIUMPH Phase 3 program covers obesity without T2D (TRIUMPH-1), with T2D (TRIUMPH-2), with cardiovascular disease (TRIUMPH-3), and with knee osteoarthritis (TRIUMPH-4). The patient profile likely to benefit most once retatrutide is approved: those who plateaued on tirzepatide despite full-dose maintenance, those with very high BMI where every additional percentage point of weight loss matters clinically, those with comorbid metabolic dysfunction-associated steatohepatitis (MASH) where the glucagon arm may contribute additional liver-fat reduction, and those whose primary clinical concern is the post-discontinuation regain pattern (because preserved resting energy expenditure may dampen regain). None of these is yet supported by retatrutide outcome data; all are mechanistic predictions based on Phase 2 results. Outside of a clinical trial, the practical answer in 2026 is that no patient should choose retatrutide — it isn't legally available. Discuss any consideration of investigational GLP-1-class agents with your physician.

Who should choose tirzepatide?

Evidence tier: 1 — FDA-approved with multi-trial Phase 3 evidence; SURMOUNT and SURPASS programs are mature.

Tirzepatide is the right choice for essentially all patients in 2026 who want a GIP-containing agent because it is the only one approved. SURMOUNT-1 produced 16-22.5% weight loss across doses; SURMOUNT-4 demonstrated continued weight loss through 88 weeks of treatment with substantial regain on placebo withdrawal; SURPASS-2 demonstrated superiority to semaglutide on A1c and weight in T2D. Zepbound carries the FDA indication for moderate-to-severe obstructive sleep apnea in obesity (December 2024), which is a unique advantage in the class. Patients with T2D, with obesity, with OSA, with MASH, or with any combination should consider tirzepatide as the default GIP-containing agent. The titration from 2.5 mg to a maintenance dose typically completes in 4-5 months, with most patients reaching effective weight loss at 7.5-15 mg weekly. Insurance coverage has expanded substantially post-Zepbound and post-OSA. Patients on tirzepatide who plateau, tolerate the drug well, and want additional weight loss are also reasonable candidates to wait for retatrutide approval rather than switching to a different mechanism. Discuss the indication match with your physician.

What does the evidence base actually say?

Evidence tier: 1 for tirzepatide; Tier 2 for retatrutide — published NEJM Phase 2 plus Phase 3 topline.

Tirzepatide has the deeper evidence base because it has been on the market since 2022. The SURMOUNT program covers obesity with and without T2D (SURMOUNT-1, -2), maintenance (SURMOUNT-4), head-to-head versus semaglutide (SURMOUNT-5), and OSA (SURMOUNT-OSA). The SURPASS program covers T2D across multiple comparators including semaglutide (SURPASS-2). The cardiovascular outcomes trial (SURPASS-CVOT) is ongoing with readout expected 2027. Retatrutide has one Phase 2 trial published in NEJM (Jastreboff 2023): 338 adults randomized to retatrutide 1, 4, 8, 12 mg or placebo, with the 12 mg arm achieving 17.5% weight loss at 24 weeks — a steeper trajectory than tirzepatide showed at the same timepoint. The Phase 3 TRIUMPH program is ongoing, with topline results pointing to ~24% weight loss at 48-72 weeks — modestly higher than tirzepatide's ~22% in SURMOUNT-1/4 at similar timepoints. There is no head-to-head retatrutide-versus-tirzepatide trial. The best evidence currently available is indirect comparison via cross-trial data, which suggests retatrutide produces deeper weight loss but is not yet sufficient for regulatory or insurance comparison.

Cost, access, and regulatory comparison

Evidence tier: 2 — FDA status and pricing reflect April 2026 reality and are subject to change as TRIUMPH data matures.

Tirzepatide is FDA-approved as Mounjaro (T2D, 2022), Zepbound (obesity, 2023), and Zepbound for OSA (December 2024). US list price is ~$1,060/month for Zepbound; insurance coverage is increasingly common in T2D, OSA, and obesity-with-comorbidity. Lilly's direct-pay program runs at meaningful discounts to list. Retatrutide is investigational. Lilly has not yet filed an NDA; FDA filing is expected in H2 2026 based on company guidance, with possible approval in 2027. There is no public list price. Compounded retatrutide is illegal in the US — the 503A and 503B compounding categories require an FDA-approved reference drug. Any "research-grade retatrutide" sold by international suppliers exists outside both the FDA framework and any quality assurance. Both share the same boxed thyroid C-cell warning class, the same pregnancy contraindication, and the same MEN-2 contraindication. See the FDA Zepbound prescribing information for current tirzepatide labeling, and Eli Lilly's TRIUMPH program page on ClinicalTrials.gov for active retatrutide trials.

Related on Peptide Story

• Retatrutide fact box
• Tirzepatide fact box
• Weight Loss pillar guide
• Semaglutide vs Tirzepatide comparison

References

• Jastreboff AM, Kaplan LM, Frías JP, et al. 2023. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. PMID 37366315
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. PMID 35658024
• Aronne LJ, Sattar N, Horn DB, et al. 2024. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. PMID 38078870
• Aronne LJ, Horn DB, le Roux CW, et al. 2025. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. PMID 40353578
• Frias JP, Davies MJ, Rosenstock J, et al. 2021. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. PMID 34170647